Verona Pharma's Ohtuvayre Defies Expectations In Q4, But Stock Alpha May Now Be Limited
Verona Pharma’s Ohtuvayre has a solid market entry, but its valuation is high. Read why VRNA stock remains a buy for ...
Verona Pharma’s Ohtuvayre: Unique COPD Solution Drives Buy Rating Amid Market Potential and Revenue Growth
Boobalan Pachaiyappan, an analyst from Roth MKM, has initiated a new Buy rating on Verona Pharma (VRNA).Stay Ahead of the Market:Discover ...
Verona Pharma initiated with a Buy at Roth MKM
Roth MKM analyst Boobalan Pachaiyappan initiated coverage of Verona Pharma (VRNA) with a Buy rating and $68 price target The firm says its ...
Verona Pharma Reports Strong Ohtuvayre™ Launch and Provides Preliminary Fourth Quarter and Full Year 2024 Financial Highlights
Approximately $36 million and $42 million net product sales of Ohtuvayre for the fourth quarter and full year 2024, ...
Verona Pharma price target raised to $74 from $64 at Wells Fargo
Wells Fargo analyst Tiago Fauth raised the firm’s price target on Verona Pharma (VRNA) to $74 from $64 and keeps an Overweight rating on the ...
Verona Pharma price target raised to $77 from $51 at BTIG
BTIG raised the firm’s price target on Verona Pharma (VRNA) to $77 from $51 and keeps a Buy rating on the shares. The company’s Q4 ...
Verona Pharma price target raised to $57 from $44 at Truist
Truist raised the firm’s price target on Verona Pharma (VRNA) to $57 from $44 and keeps a Buy rating on the shares. The firm cites the ...
Nasdaq3d
Verona Pharma Reports Approximately $36 Million in Q4 2024 Net Sales for Ohtuvayre with Strong Prescription Growth
Verona Pharma reports $36M in Q4 and $42M in 2024 sales for Ohtuvayre, with over 16,000 prescriptions filled. Verona Pharma plc has announced its preliminary unaudited net product sales for ...
Verona Pharma Expects Preliminary Q4 Sales Of About $36 Mln From Ohtuvayre
Verona Pharma plc (VRNA), a biopharmaceutical company, Tuesday announced that the company expects preliminary unaudited fourth ...
Truist Financial Remains a Buy on Verona Pharma (VRNA)
In a report released today, Joon Lee from Truist Financial maintained a Buy rating on Verona Pharma (VRNA – Research Report). The company’s ...
Business Insider3d
Verona Pharma Reports Strong Ohtuvayre™ Launch and Provides Preliminary Fourth Quarter and Full Year 2024 Financial Highlights
For further information please contact: Verona Pharma is a biopharmaceutical company focused on developing and commercializing innovative therapies for the treatment of chronic respiratory ...